Our data confirm that IL-2 and IL-15 improve CD8+ T cell activation and induction of prophylactic tumor immunity, also when incorporated in a coronavirus-based vaccine that delivers the cytokines directly to DCs in vivo. The gene discussed is CD8A; the disease is neoplasm.